Dr. Benjamin Wolozin to Present "Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology" at CTAD 2023
Retrieved on:
Tuesday, October 24, 2023
FDA, MIT, Cognition, Vaccine, Neuron, Hope, Takeda, Neurology, LabCentral, Pathology, Boston Park Plaza, Entrepreneurship, Research, Protein, Manhattan Center, Brain damage, Anatomy, Pfizer, ALS, Boston University School of Public Health, Killing Floor 2, Tau, AbbVie, Foundation for the National Institutes of Health, Patient, Kendall Square, Neuroscience, Alzheimer's Association, Memory, Pharmaceutical industry, Medical imaging, Alzheimer's disease
CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of neurodegenerative disorders, today announced that the company's Co-Founder and Chief Scientific Officer, Dr. Benjamin Wolozin MD, Ph.D., will be presenting new preclinical research at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference. CTAD is the premier industry event highlighting new research and breakthroughs in the areas of disease-modifying agents, gene therapy, vaccines and multimodal interventions.
Key Points:
- CTAD is the premier industry event highlighting new research and breakthroughs in the areas of disease-modifying agents, gene therapy, vaccines and multimodal interventions.
- CTAD 23 is sold out, but attendees can still register for virtual attendance.
- Our therapeutic removes abnormal tau protein, which is the key protein contributing to loss of memory and cognition in Alzheimer's disease.
- If successful in clinical trials, Aquinnah's treatment offers the hope of reducing the brain damage and correspondingly restoring brain function for patients suffering from Alzheimer's disease."